// App-Quantinova.ai

2638 : A High Complete Remission Rate Can Be Achieved In Older Patients (Age ?60) With Acute Lymphoblastic Leukemia Regardless Of Induction Intensities: Single-Institution Experience At Memorial Sloan-Kettering Cancer Center

Researchers

Presenter

  • Jae H Park

Principal Investigators

  • Steven Lee

  • Sean M. Devlin

  • Martin S Tallman

  • Dan Douer

Medical Centers

  • Lymphoma Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY

  • Department of Biostatistics and Epidemiology, Memorial Sloan-Kettering Cancer Center, New York, NY

  • Department of Internal Medicine, St. Luke's-Roosevelt Hospital Center, New York, NY

  • Department of Medicine, Leukemia Service, Memorial Sloan Kettering Cancer Center, New York, NY

  • Leukemia Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, Weill Cornell Medical College, New York, NY

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Acute lymphoblastic leukemia

  • Solid malignancies

  • B-cell acute lymphoblastic leukemia

  • T-cell acute lymphoblastic leukemia

Biomarkers

  • Ph chromosome

Drug/Treatment

  • Vincristine

  • dasatinib

  • Imatinib

  • IkT001

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved